Cargando…
Ferrostatin‐1‐loaded liposome for treatment of corneal alkali burn via targeting ferroptosis
Alkali burn is a potentially blinding corneal injury. During the progression of alkali burn‐induced injury, overwhelmed oxidative stress in the cornea triggers cell damage, including oxidative changes in cellular macromolecules and lipid peroxidation in membranes, leading to impaired corneal transpa...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115688/ https://www.ncbi.nlm.nih.gov/pubmed/35600640 http://dx.doi.org/10.1002/btm2.10276 |
_version_ | 1784709972127383552 |
---|---|
author | Wang, Kai Jiang, Li Zhong, Yueyang Zhang, Yin Yin, Qichuan Li, Su Zhang, Xiaobo Han, Haijie Yao, Ke |
author_facet | Wang, Kai Jiang, Li Zhong, Yueyang Zhang, Yin Yin, Qichuan Li, Su Zhang, Xiaobo Han, Haijie Yao, Ke |
author_sort | Wang, Kai |
collection | PubMed |
description | Alkali burn is a potentially blinding corneal injury. During the progression of alkali burn‐induced injury, overwhelmed oxidative stress in the cornea triggers cell damage, including oxidative changes in cellular macromolecules and lipid peroxidation in membranes, leading to impaired corneal transparency, decreased vision, or even blindness. In this study, we identified that ferroptosis, a type of lipid peroxidation‐dependent cell death, mediated alkali burn‐induced corneal injury. Ferroptosis‐targeting therapy protected the cornea from cell damage and neovascularization. However, the specific ferroptosis inhibitor ferrostatin‐1 (Fer‐1) is hydrophobic and cannot be directly applied in the clinic. Therefore, we developed Fer‐1‐loaded liposomes (Fer‐1‐NPs) to improve the bioavailability of Fer‐1. Our study demonstrated that Fer‐1‐NPs exerted remarkable curative effects regarding corneal opacity and neovascularization in vivo. The efficacy was comparable to that of dexamethasone, but without appreciable side effects. The significant suppression of ferroptosis (induced by lipid peroxidation and mitochondria disruption), inflammation, and neovascularization might be the mechanisms underlying the therapeutic effect of Fer‐1‐NPs. Moreover, the Fer‐1‐NPs treatment showed no signs of cytotoxicity, hematologic toxicity, or visceral organ damage, which further confirmed the biocompatibility. Overall, Fer‐1‐NPs provide a new prospect for safe and effective therapy for corneal alkali burn. |
format | Online Article Text |
id | pubmed-9115688 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91156882022-05-20 Ferrostatin‐1‐loaded liposome for treatment of corneal alkali burn via targeting ferroptosis Wang, Kai Jiang, Li Zhong, Yueyang Zhang, Yin Yin, Qichuan Li, Su Zhang, Xiaobo Han, Haijie Yao, Ke Bioeng Transl Med Research Articles Alkali burn is a potentially blinding corneal injury. During the progression of alkali burn‐induced injury, overwhelmed oxidative stress in the cornea triggers cell damage, including oxidative changes in cellular macromolecules and lipid peroxidation in membranes, leading to impaired corneal transparency, decreased vision, or even blindness. In this study, we identified that ferroptosis, a type of lipid peroxidation‐dependent cell death, mediated alkali burn‐induced corneal injury. Ferroptosis‐targeting therapy protected the cornea from cell damage and neovascularization. However, the specific ferroptosis inhibitor ferrostatin‐1 (Fer‐1) is hydrophobic and cannot be directly applied in the clinic. Therefore, we developed Fer‐1‐loaded liposomes (Fer‐1‐NPs) to improve the bioavailability of Fer‐1. Our study demonstrated that Fer‐1‐NPs exerted remarkable curative effects regarding corneal opacity and neovascularization in vivo. The efficacy was comparable to that of dexamethasone, but without appreciable side effects. The significant suppression of ferroptosis (induced by lipid peroxidation and mitochondria disruption), inflammation, and neovascularization might be the mechanisms underlying the therapeutic effect of Fer‐1‐NPs. Moreover, the Fer‐1‐NPs treatment showed no signs of cytotoxicity, hematologic toxicity, or visceral organ damage, which further confirmed the biocompatibility. Overall, Fer‐1‐NPs provide a new prospect for safe and effective therapy for corneal alkali burn. John Wiley & Sons, Inc. 2021-12-08 /pmc/articles/PMC9115688/ /pubmed/35600640 http://dx.doi.org/10.1002/btm2.10276 Text en © 2021 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Wang, Kai Jiang, Li Zhong, Yueyang Zhang, Yin Yin, Qichuan Li, Su Zhang, Xiaobo Han, Haijie Yao, Ke Ferrostatin‐1‐loaded liposome for treatment of corneal alkali burn via targeting ferroptosis |
title | Ferrostatin‐1‐loaded liposome for treatment of corneal alkali burn via targeting ferroptosis |
title_full | Ferrostatin‐1‐loaded liposome for treatment of corneal alkali burn via targeting ferroptosis |
title_fullStr | Ferrostatin‐1‐loaded liposome for treatment of corneal alkali burn via targeting ferroptosis |
title_full_unstemmed | Ferrostatin‐1‐loaded liposome for treatment of corneal alkali burn via targeting ferroptosis |
title_short | Ferrostatin‐1‐loaded liposome for treatment of corneal alkali burn via targeting ferroptosis |
title_sort | ferrostatin‐1‐loaded liposome for treatment of corneal alkali burn via targeting ferroptosis |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115688/ https://www.ncbi.nlm.nih.gov/pubmed/35600640 http://dx.doi.org/10.1002/btm2.10276 |
work_keys_str_mv | AT wangkai ferrostatin1loadedliposomefortreatmentofcornealalkaliburnviatargetingferroptosis AT jiangli ferrostatin1loadedliposomefortreatmentofcornealalkaliburnviatargetingferroptosis AT zhongyueyang ferrostatin1loadedliposomefortreatmentofcornealalkaliburnviatargetingferroptosis AT zhangyin ferrostatin1loadedliposomefortreatmentofcornealalkaliburnviatargetingferroptosis AT yinqichuan ferrostatin1loadedliposomefortreatmentofcornealalkaliburnviatargetingferroptosis AT lisu ferrostatin1loadedliposomefortreatmentofcornealalkaliburnviatargetingferroptosis AT zhangxiaobo ferrostatin1loadedliposomefortreatmentofcornealalkaliburnviatargetingferroptosis AT hanhaijie ferrostatin1loadedliposomefortreatmentofcornealalkaliburnviatargetingferroptosis AT yaoke ferrostatin1loadedliposomefortreatmentofcornealalkaliburnviatargetingferroptosis |